AI Weekly Malaysia

Biotech startup Vivodyne argues AI drug discovery is bottlenecked by a lack of causal biological data from living human tissue, not compute or model architecture. Its HIVE robotic labs grow 20 kinds of human tissue and autonomously dose and monitor them to generate the data that current models lack. The article also notes that AlphaFold has yet to produce a new drug, Isomorphic Labs' first trials are delayed to end of 2026, and even Anthropic's Dario Amodei now calls AI-cures-cancer claims 'more cliche than credible.'

Why: For AI/ML builders and founders, this is a concrete reminder that model capability is often gated by training data quality and availability, not scale — the same pattern applies outside biotech. If you're building AI products, ask whether your bottleneck is actually data you don't have, and whether you need to build infrastructure to generate it rather than throwing more compute at the problem.

The Xen Project has formed a Safety Committee and created a new 'Premier Plus' membership tier to pursue formal safety certification (IEC-61508) for its open-source hypervisor, targeting embedded use cases like cars and robots where workload isolation prevents non-critical apps from crashing safety-critical functions. Founding contributors are AMD, EPAM, and Renesas, and Boeing has quietly joined the project. The initiative aims to maintain shared engineering evidence alongside the code to reduce duplicated certification effort across organizations.

Why: If you build or deploy embedded/robotics systems that mix safety-critical and non-critical workloads on shared hardware, Xen is positioning itself as a certifiable open-source partitioning option—worth tracking if you currently evaluate proprietary hypervisors for automotive or industrial deployments. For most web/AI/SaaS builders in this community, there is no immediate action to take.